ASCOR Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Ascor, and what generic alternatives are available?
Ascor is a drug marketed by Mcguff and is included in one NDA.
The generic ingredient in ASCOR is ascorbic acid. There are six drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the ascorbic acid profile page.
Summary for ASCOR
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 171 |
| Patent Applications: | 4,868 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for ASCOR |
| Drug Sales Revenues: | Drug sales revenues for ASCOR |
| What excipients (inactive ingredients) are in ASCOR? | ASCOR excipients list |
| DailyMed Link: | ASCOR at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for ASCOR
Generic Entry Date for ASCOR*:
Constraining patent/regulatory exclusivity:
FOR TREATMENT OF SCURVY IN ADULT AND PEDIATRIC PATIENTS AGE 5 MONTHS AND OLDER FOR WHOM ORAL ADMINISTRATION IS NOT POSSIBLE, INSUFFICIENT OR CONTRAINDICATED NDA:
Dosage:
SOLUTION;INTRAVENOUS |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Pharmacology for ASCOR
| Drug Class | Vitamin C |
Anatomical Therapeutic Chemical (ATC) Classes for ASCOR
US Patents and Regulatory Information for ASCOR
ASCOR is protected by zero US patents and one FDA Regulatory Exclusivity.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of ASCOR is ⤷ Try a Trial.
This potential generic entry date is based on FOR TREATMENT OF SCURVY IN ADULT AND PEDIATRIC PATIENTS AGE 5 MONTHS AND OLDER FOR WHOM ORAL ADMINISTRATION IS NOT POSSIBLE, INSUFFICIENT OR CONTRAINDICATED.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
FDA Regulatory Exclusivity protecting ASCOR
FOR TREATMENT OF SCURVY IN ADULT AND PEDIATRIC PATIENTS AGE 5 MONTHS AND OLDER FOR WHOM ORAL ADMINISTRATION IS NOT POSSIBLE, INSUFFICIENT OR CONTRAINDICATED
Exclusivity Expiration: ⤷ Try a Trial
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mcguff | ASCOR | ascorbic acid | SOLUTION;INTRAVENOUS | 209112-001 | Oct 2, 2017 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
